Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of adjuvanted quadrivalent influenza vaccine in children 6 to <72 months
2012-000218-12Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of MF59-adjuvanted quadrivalent influenza vaccine and Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) in influenza (2 arms), sponsored by CSL Seqirus. Primary endpoints: Primary efficacy endpoint and Relative efficacy by RT-PCR-confirmed influenza. Started Aug 2013; status: completed.
02
Drugs
MF59-adjuvanted quadrivalent influenza vaccineInfluenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2012-000218-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000218-12.